Atai Life Sciences N.V. (ATAI)

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) chief scientific officer Glenn Short spoke with Proactive about the company's recent NIH grant and its innovative discovery program targeting opioid use disor...

Atai Life Sciences N.V. has surged >275% YTD, driven by promising psychedelic drug candidates targeting treatment-resistant depression and other mental health disorders. ATAI's lead asset, BPL-003, sh...

Atai Life Sciences (ATAI 14.96%), an ambitious biotech that targets mental health disorders, was a hot item among equity investors Tuesday. The company saw its share price rise by just under 15% that ...

Atai Life Sciences ATAI and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen of BPL-0...

Shares in atai Life Sciences (NASDAQ:ATAI, ETR:9VC) rose 10% on Tuesday after the company and its UK partner Beckley Psytech reported encouraging mid-stage trial results for their experimental nasal s...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) and Beckley Psytech said Tuesday that their experimental nasal spray for depression showed promising results in a mid-stage clinical trial, bolstering hopes f...

Here is how atai Life Sciences N.V. (ATAI) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has been awarded a grant of up to $11.4 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health ...

atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Atai Life Sciences N.V. (NASDAQ:ATAI ) H.C.